Trial Condition(s):

N/A

Dose-escalating Phase I study to define the safety profile, pharmacokinetics, pharmacodynamics and tumor response profile of BAY 43-9006 in combination with oxaliplatin chemotherapy in patients

Bayer Identifier:

10954

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
37
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Locations
Status
LocationsStatus

For details, please refer to trial results

Additional Information